文献速递类风湿关节炎其他结缔组织病

MUC5B启动子变异rs35705950与类风湿关节炎相关间质性肺病的生存和进展

MUC5B promoter variant rs35705950 and rheumatoid arthritis associated interstitial lung disease survival and progression.
PubMed 文献 · Semin Arthritis Rheum · 2021-07-10

本研究为国际多中心回顾性观察研究,纳入261例类风湿关节炎相关间质性肺病(RA-ILD)患者,分析MUC5B rs35705950变异与无肺移植生存及肺功能进展的关系。结果显示该变异未影响无肺移植生存(HR=1.26,95%CI 0.61-2.62,P=0.53),也未影响2年肺功能下降(OR=0.95,95%CI 0.44-2.05,P=0.89)。

要点

  • MUC5B rs35705950变异未影响RA-ILD患者无肺移植生存。
  • 该变异未影响RA-ILD患者2年肺功能下降。
  • 结果不受HRCT模式影响。

核心结论

  • MUC5B rs35705950启动子变异未影响RA-ILD患者的无肺移植生存或肺功能下降。

研究设计与样本

  • 国际回顾性观察研究,261例RA-ILD患者进行MUC5B rs35705950基因分型并收集连续肺功能检查,随访长达10年,采用混合回归模型、比例风险模型和联合比例风险模型分析。

主要发现

  • 10年死亡率为32%(95%CI 19-42)。
  • T风险等位基因携带者无肺移植生存的HR=1.26(95%CI 0.61-2.62,P=0.53)。
  • 2年肺功能下降的OR=0.95(95%CI 0.44-2.05,P=0.89),不受HRCT模式影响。

关键数值与推荐

  • RA-ILD显著进展定义为基线后2年内用力肺活量绝对或相对下降至少10%。

临床怎么用

  • MUC5B rs35705950变异不宜用于预测RA-ILD患者的生存或肺功能进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The major risk factor for idiopathic pulmonary fibrosis (IPF), MUC5B rs35705950, was found to be associated with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Whilst the MUC5B rs35705950 T risk allele has been associated with better survival in IPF, its impact on RA-ILD prognosis remains to be determined. Our objective was to explore the influence of MUC5B rs35705950 on survival and progression in RA-ILD. METHODS: Through an international retrospective observational study, patients with RA-ILD were genotyped for the MUC5B rs35705950 variant and consecutive pulmonary function tests (PFTs) findings were collected. Longitudinal data up to a 10-year follow-up were considered and analyzed using mixed regression models. Proportional hazards and joint proportional hazards models were used to analyze the association of baseline and longitudinal variables with lung transplant-free survival. Significant progression of RA-ILD was defined as at least an absolute or relative 10% decline of forced vital capacity at 2 years from baseline. RESULTS: Out of 321 registered patients, 261 were included in the study: 139 women (53.3%), median age at RA-ILD diagnosis 65 years (interquartile range [IQR] 57 to 71), 151 ever smokers (59.2%). Median follow-up was 3.5 years (IQR 1.3 to 6.6). Mortality rate was 32% (95%CI 19 to 42) at 10 years. The MUC5B rs35705950 variant did not impact lung transplant-free survival (HR for the T risk allele carriers=1.26; 95%CI 0.61 to 2.62; P=0.53). Decline in pulmonary function at 2 years was not influenced by MUC5B rs35705950 (OR=0.95; 95%CI 0.44 to 2.05; P=0.89), irrespective of the HRCT pattern. CONCLUSION: In this study, the MUC5B rs35705950 promoter variant did not influence transplant- free survival or decline in pulmonary function in patients with RA-ILD.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Juge PA, Solomon JJ, van Moorsel CHM, et al. MUC5B promoter variant rs35705950 and rheumatoid arthritis associated interstitial lung disease survival and progression. Semin Arthritis Rheum. 2021. PMID: 34411838. doi:10.1016/j.semarthrit.2021.07.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。